The damaging effect of passenger mutations on cancer progression

Cancer Research

Volumn 77, Issue 18, 2017, Pages 4763-4772

  McFarland, Christopher D ^a   Yaglom, Julia A ^b   Wojtkowiak, Jonathan W ^c   Scott, Jacob G ^d   Morse, David L ^c   Sherman, Michael Y ^b   Mirny, Leonid A ^e,f  

^a STANFORD UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e Massachusetts Institute of Technology   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HISTONE H2AX; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CANCER FITNESS; CANCER GROWTH; CELL DIVISION; CELL STRESS; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE MUTATION; GENERAL ASPECTS OF DISEASE; GENETIC ASSOCIATION; GENETIC TRANSFECTION; GENOMIC INSTABILITY; GENOMICS; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MCF 10A CELL LINE; METASTASIS POTENTIAL; METASTATIC BURDEN; MOUSE; MUTATION RATE; NONHUMAN; ONCOLOGICAL PARAMETERS; PASSENGER LOAD; PASSENGER MUTATION; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TIME SERIES ANALYSIS; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BREAST; BREAST TUMOR; CELL CULTURE; CELL TRANSFORMATION; DISEASE COURSE; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY; SCID MOUSE; SECONDARY;

ANIMALS; BIOMARKERS, TUMOR; BREAST; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; MUTATION;

EID: 85031765447     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3283-T     Document Type: Article

References (50)

1. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501:338–45.
2. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546–58.
3. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505:495–501.
4. Castro-giner F, Ratcliffe P, Tomlinson I. The mini-driver model of polygenic cancer evolution. Nat Rev Cancer 2015;15:680–5.
5. Nussinov R, Tsai C. Science Direct "Latent drivers" expand the cancer mutational landscape. Curr Opin Struct Biol 2015;32:25–32.
6. Merlo LMF, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006;6:924–35.
7. Bozic I, Gerold JM, Nowak MA. Quantifying clonal and subclonal passenger mutations in cancer evolution. PLoS Comput Biol 2016;12: e1004731.
8. McFarland CD, Korolev KS, Kryukov GV, Sunyaev SR, Mirny LA. Impact of deleterious passenger mutations on cancer progression. Proc Natl Acad Sci U S A 2013;110:2910–5.
9. McFarland CD, Mirny LA, Korolev KS. Tug-of-war between driver and passenger mutations in cancer and other adaptive processes. Proc Natl Acad Sci U S A 2014;111:15138–43.
10. Kelly LM, Barila G, Liu P, Evdokimova VN, Trivedi S. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. 2014;111:4233–8.
11. Kimura M. Model of effectively neutral mutations in which selective constraint is incorporated. 1979;76:3440–4.
12. Paland S, Lynch M. Transitions to asexuality result in excess amino acid substitutions. Science 2006;311:990–2.
13. Gabriel W, Lynch M, Burger R. Muller's ratchet and mutational meltdowns. Evolution 1993;47:1744.
14. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Article molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2014;160:48–61.
15. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014;515:572–6.
16. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577–81.
17. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189–99.
18. Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 2011;71:3447–52.
19. Sheltzer JM, Amon A. The aneuploidy paradox: costs and benefits of an incorrect karyotype. Trends Genet 2011;27:446–53.
20. Andor N, Graham TA, Jansen M, Xia LC, Aktipis CA, Petritsch C, et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med 2015;22:105–13.
21. Williams BR, Prabhu VR, Hunter KE, Glazier CM, Whittaker CA, Housman DE, et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 2008;322:703–9.
22. Weaver BAA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007;11:25–36.
23. Schvartzman J-M, Sotillo R, Benezra R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer 2010;10:102–15.
24. Yaglom JA, McFarland C, Mirny L, Sherman MY. Oncogene-triggered suppression of DNA repair leads to DNA instability in cancer. Oncotarget 2014;5:8367–78.
25. Klambauer G, Schwarzbauer K, Mayr A, Clevert DA, Mitterecker A, Bodenhofer U, et al. Cn.MOPS: Mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate. Nucleic Acids Res 2012;40:1–14.
26. Guberman JM, Ai J, Arnaiz O, Baran J, Blake A, Baldock R, et al. BioMart Central Portal: an open database network for the biological community. Database 2011;2011:bar041.
27. Eisenberg E, Levanon EY. Human housekeeping genes, revisited. Trends Genet 2013;29:569–74.
28. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res 2002;12: 996–1006.
29. Aceto N, Duss S, MacDonald G, Meyer DS, Roloff TC, Hynes NE, et al. Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion. Breast Cancer Res 2012;14:R131.
30. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400–4.
31. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in Python. J Mach Learn Res 2011; 12:2825–30.
32. Sherman MY, Meng L, Stampfer M, Gabai VL, Yaglom JA. Oncogenes induce senescence with incomplete growth arrest and suppress the DNA damage response in immortalized cells. Aging Cell 2011;10: 949–61.
33. Quiles JL, Huertas JR, Battino M, Mataix J, Ramírez-Tortosa MC. Antioxidant nutrients and adriamycin toxicity. Toxicology 2002;180: 79–95.
34. Donahue SL, Lin Q, Cao S, Ruley HE. Carcinogens induce genome-wide loss of heterozygosity in normal stem cells without persistent chromosomal instability. Proc Natl Acad Sci U S A 2006;103:11642–6.
35. Fudenberg G, Getz G, Meyerson M, Mirny LA. High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. Nat Biotechnol 2011;29:1109–13.
36. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013;45:1134–40.
37. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006;38:1043–8.
38. Vermeulen L, Morrissey E, van der Heijden M, Nicholson AM, Sottoriva A, Buczacki S, et al. Defining stem cell dynamics in models of intestinal tumor initiation. Science 2013;342:995–8.
39. Duesberg P, Stindl R, Hehlmann R. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassort-ments that are catalyzed by aneuploidy. Proc Natl Acad Sci U S A 2000;97:14295–300.
40. Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 2012;18:5806–15.
41. Frank SA. Dynamics of cancer: Incidence, Inheritance, and Evolution. Princeton, NJ: Princeton University Press; 2007.
42. Jackson AL, Loeb LA. The mutation rate and cancer. Genetics 1998;148: 1483–90.
43. Good BH, Desai MM. Deleterious passengers in adapting populations. 2014;198:1–25.
44. Charlesworth B, Morgan MT, Charlesworth D. The effect of deleterious mutations on neutral molecular variation. Genetics 1993;134:1289–303.
45. Bachtrog D, Gordo I. Adaptive evolution of asexual populations under Muller's ratchet. Evolution 2004;58:1403–13.
46. Boyko AR, Williamson SH, Indap AR, Degenhardt JD, Hernandez RD, Lohmueller KE, et al. Assessing the evolutionary impact of amino acid mutations in the human genome. PLoS Genet 2008;4:e1000083.
47. Jordan DM, Ramensky VE, Sunyaev SR. Human allelic variation: perspective from protein function, structure, and evolution. Curr Opin Struct Biol 2010;20:342–50.
48. Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 2012;488:337–42.
49. Lee AJX, Swanton C. Tumour heterogeneity and drug resistance: persona-lising cancer medicine through functional genomics. Biochem Pharmacol 2012;83:1013–20.
50. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat 1979;7:1–26.